The systemic complement activation caused by interleukin-2/lymphokine-activated killer-cell therapy of cancer causes minimal systemic neutrophil activation. [electronic resource]
Producer: 19911121Description: 504-8 p. digitalISSN:- 0020-7136
- Chemotaxis, Leukocyte -- drug effects
- Complement Activation -- drug effects
- Complement System Proteins -- analysis
- Humans
- In Vitro Techniques
- Interleukin-2 -- therapeutic use
- Killer Cells, Lymphokine-Activated
- N-Formylmethionine Leucyl-Phenylalanine -- pharmacology
- Neoplasms -- blood
- Neutrophils -- drug effects
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.